The author went hunting for a catch in the phase 3 numbers and says none turned up, while admitting the results made them uneasy.
Recap by typeshit. Post by Facebook on Facebook.
The once-daily pill blocks the IL-23 receptor and helped people with moderate to severe ulcerative colitis respond more often than placebo, a new study reports.
Bikman welcomes a new result but argues the likely cause is tirzepatide bringing insulin down rather than the drug slowing aging itself. His view, not a study claim.
Marchione makes the case for pairing GLP-1s with drugs that target amylin, the hormone released after meals that signals fullness to the brain.
Regen says the placebo group saw a 9% drop, while people on retatrutide also lost 31 lb on average and saw systolic blood pressure fall 14 points.
People familiar with the matter say the plan under review includes more safeguards for patients than first expected. A policy step worth watching.
Stanford doctors look at what peptides are and whether the online wellness hype holds up, covering possible upsides alongside the risks.
Loading…